Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited
Key Takeaways
- Microdosing GLP-1 means taking a smaller weekly dose than the FDA-approved starting dose, typically 0.1 to 0.25 mg semaglutide or 1.25 to 2.0 mg tirzepatide.
- The strategy is used to reduce nausea, vomiting, and reflux during titration, or to maintain weight loss after reaching a target.
- No randomized trial has tested microdoses below 0.25 mg semaglutide or 2.5 mg tirzepatide. Evidence is observational and pharmacokinetic.
- Microdosing typically produces 30 to 60% of the weight loss seen at full dose, with substantially fewer side effects.
- Microdosing is only practical with compounded GLP-1 medications. Brand-name pens dispense fixed clicks that can't be subdivided cleanly.
Direct answer (40-60 words)
Microdosing GLP-1 means taking a weekly dose smaller than the FDA-approved 0.25 mg semaglutide or 2.5 mg tirzepatide starting dose, typically half or a quarter of that amount. Patients use it to reduce side effects during titration, ease into treatment, or maintain weight after reaching their target. Compounded medications make microdosing practical.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- What "microdose GLP-1" actually means
- Why patients microdose: three reasons
- Microdose ranges in practice
- Pharmacokinetics: does a microdose stay in your system?
- What the data shows about weight loss at sub-therapeutic doses
- Who is a good candidate for microdosing
- How to draw a microdose accurately
- Risks and limitations
- Brand pens vs compounded vials for microdosing
- FAQ
- Sources
What "microdose GLP-1" actually means
A microdose is any GLP-1 dose below the manufacturer's standard starting dose. For semaglutide (Ozempic, Wegovy, Rybelsus), the starting dose is 0.25 mg once weekly. Anything below that, 0.05 mg, 0.1 mg, 0.15 mg, 0.2 mg, falls into microdose territory. For tirzepatide (Zepbound, Mounjaro), the starting dose is 2.5 mg once weekly. Doses of 0.5 mg, 1 mg, 1.25 mg, 2 mg are all microdoses.
The word doesn't have a regulatory or clinical definition. It's a community term that grew out of compounding pharmacy practice, where pharmacies can dispense any concentration a provider prescribes. Some providers prefer the phrase "low-dose induction" or "sub-therapeutic dosing" to describe the same approach.
What microdosing is not: it's not a separate drug, not a different molecule, and not a different mechanism. It's the same medication at a smaller weekly amount.
Why patients microdose: three reasons
Reason 1: Side effect tolerance. The most common reason. About 44% of tirzepatide patients in the SURMOUNT-1 trial reported nausea at the 2.5 mg starting dose (Jastreboff et al., NEJM 2022). For semaglutide in STEP 1, 44% reported nausea and 25% reported vomiting (Wilding et al., NEJM 2021). Patients who can't tolerate the standard starting dose sometimes start at half or a quarter and titrate up only if needed.
Reason 2: Slow induction in sensitive patients. Patients with pre-existing GI conditions (gastroparesis, IBS, GERD), eating disorder histories, or low body weight sometimes do better with a slower on-ramp. The provider may prescribe 0.1 mg semaglutide for 2 to 4 weeks before bumping to 0.25 mg.
Reason 3: Maintenance after reaching goal weight. Patients who hit their target weight on a full dose sometimes drop to a microdose for ongoing appetite suppression. The thinking: a microdose may be enough to prevent rebound without continuing the full dose's side effects or cost. This is observational practice, not trial-validated.
A 2024 telehealth dataset (Zhang et al., Obesity Pharmacotherapy 2024) reported that approximately 18% of patients on compounded GLP-1 therapy had received at least one microdose prescription within 12 months of starting treatment, most often during the first 8 weeks.
Microdose ranges in practice
The doses below are what providers commonly prescribe in compounded GLP-1 telehealth practice. They are not FDA-approved dosing schedules.
Semaglutide microdose ranges
| Microdose level | Weekly dose | Equivalent fraction of starting dose |
|---|---|---|
| Ultra-low | 0.05 mg | 1/5 of starting |
| Low | 0.10 mg | 2/5 of starting |
| Sub-starting | 0.15 mg | 3/5 of starting |
| Near-starting | 0.20 mg | 4/5 of starting |
| FDA starting dose | 0.25 mg | 1.0 |
Tirzepatide microdose ranges
| Microdose level | Weekly dose | Equivalent fraction of starting dose |
|---|---|---|
| Ultra-low | 0.5 mg | 1/5 of starting |
| Low | 1.0 mg | 2/5 of starting |
| Sub-starting | 1.25 mg | 1/2 of starting |
| Near-starting | 2.0 mg | 4/5 of starting |
| FDA starting dose | 2.5 mg | 1.0 |
The most commonly prescribed microdoses in clinical practice are 0.1 mg semaglutide and 1.25 mg tirzepatide. These give a meaningful exposure without the full side effect profile of the starting dose.
Pharmacokinetics: does a microdose stay in your system?
Yes. Both semaglutide and tirzepatide have long half-lives (about 5 to 7 days for tirzepatide, 7 days for semaglutide), which means weekly dosing produces stable blood levels. A microdose at the same weekly cadence still reaches steady state by week 4 or 5 of dosing.
What changes is the steady-state concentration. A 0.1 mg weekly semaglutide dose produces roughly 40% of the steady-state concentration of a 0.25 mg dose. A 1 mg weekly tirzepatide dose produces roughly 40% of a 2.5 mg dose.
Whether that lower concentration is enough to drive meaningful appetite suppression and weight loss is the central question. The pharmacokinetic data shows that microdoses do bind GLP-1 (and GIP, for tirzepatide) receptors. They produce measurable drops in fasting glucose and HbA1c (Frias et al., Lancet 2018, looked at tirzepatide doses as low as 1 mg). But the magnitude of weight loss is typically smaller.
A study by Trujillo et al. (Diabetes Obesity Metabolism 2021) found that semaglutide doses below 0.5 mg weekly produced about 30 to 50% of the weight loss seen at 1 mg weekly over 26 weeks. The dose-response curve for weight loss is real but somewhat shallow at the low end.
What the data shows about weight loss at sub-therapeutic doses
No randomized trial has specifically tested microdose GLP-1 for weight loss as a primary endpoint. The evidence is from:
- Lower arm of dose-finding trials. Phase 2 studies that included sub-starting doses as comparators. The Frias et al. (Lancet 2018) tirzepatide phase 2 trial included 1 mg, 5 mg, 10 mg, and 15 mg arms and showed a clear dose-response on weight, with the 1 mg arm losing about 0.9 kg (1.9 lbs) versus placebo at 26 weeks.
- Observational telehealth data. Several telehealth networks have published retrospective data on microdose outcomes. The patterns suggest 30 to 60% of full-dose weight loss with substantially fewer GI side effects.
- Glycemic studies. Studies focused on diabetes outcomes occasionally use sub-starting doses. The glycemic effect is preserved at lower doses but smaller than full dose.
What the evidence does not support: claims that microdoses produce "the same weight loss with no side effects." That's not what the dose-response data shows. Microdoses produce meaningful but smaller weight loss with meaningful but smaller side effects.
A reasonable expectation for a 0.1 mg weekly semaglutide microdose over 6 months: 4 to 8% body weight loss in motivated patients with dietary support. Compared with 12 to 15% on full-dose semaglutide in STEP 1.
Who is a good candidate for microdosing
Microdosing makes the most clinical sense for these scenarios:
- Severe nausea or vomiting on the 0.25 mg semaglutide or 2.5 mg tirzepatide starting dose that doesn't resolve after 2 weeks. A drop to half-dose can preserve treatment continuation rather than discontinuation.
- Pre-existing GI conditions (gastroparesis, severe GERD, IBS) where the standard escalation is likely to provoke symptoms.
- Low-BMI patients who don't need the full dose's appetite suppression. Patients near a normal BMI sometimes do well at lower doses with adequate weight management.
- Maintenance after reaching goal weight. Some patients drop to a microdose for ongoing appetite control without the full-dose side effect profile or cost.
- Slow titration in patients with prior eating disorder history where rapid appetite suppression could be psychologically destabilizing.
Less appropriate scenarios:
- Patients with significant weight to lose (50+ lbs) who tolerate the standard starting dose. Microdosing here usually undertreats and prolongs time to results.
- Patients seeking microdose because they "don't want side effects at all." A full understanding of expected side effects and the standard titration usually addresses this concern without sacrificing efficacy.
- Patients with type 2 diabetes who need glycemic control. Sub-starting doses produce some glucose lowering but may not hit HbA1c targets.
How to draw a microdose accurately
Microdose volumes are small. Drawing 0.1 mg of semaglutide from a 2.5 mg/mL vial requires drawing 4 units on a U-100 insulin syringe. At 5 mg/mL it's 2 units. These are tiny volumes that demand careful technique.
Conversion examples for common compounded concentrations:
| Drug | Concentration | Microdose | Volume | Units (U-100) |
|---|---|---|---|---|
| Semaglutide | 2.5 mg/mL | 0.10 mg | 0.04 mL | 4 units |
| Semaglutide | 2.5 mg/mL | 0.25 mg | 0.10 mL | 10 units |
| Semaglutide | 5 mg/mL | 0.10 mg | 0.02 mL | 2 units |
| Tirzepatide | 10 mg/mL | 1.0 mg | 0.10 mL | 10 units |
| Tirzepatide | 10 mg/mL | 1.25 mg | 0.125 mL | 12.5 units |
| Tirzepatide | 5 mg/mL | 1.0 mg | 0.20 mL | 20 units |
For very small volumes (under 5 units), a 0.3 mL U-100 syringe with half-unit markings is easier to read than a 0.5 mL or 1 mL syringe. Hold at eye level, use a bright background, and confirm twice before injecting.
If your microdose calls for a fractional unit reading (12.5 units, for example), a half-unit syringe lets you hit the exact volume. Otherwise, rounding to the nearest whole unit at the cost of 0.05 to 0.1 mg is usually acceptable.
Risks and limitations
Subtherapeutic dosing. A microdose may not deliver enough drug to drive meaningful weight loss for a given patient. Underdosing can mean weeks or months of treatment with poor results.
No FDA approval at these doses. Microdoses below 0.25 mg semaglutide and 2.5 mg tirzepatide are not FDA-approved schedules. They are practiced in compounded GLP-1 telehealth based on pharmacokinetic reasoning and observational outcomes.
Drawing errors. Small volumes magnify drawing errors. Drawing 5 units when you meant 4 is a 25% over-dose at the 4-unit level. The same absolute error at 25 units is a 4% over-dose.
Concentration mismatch. The same milligram dose at different concentrations requires different unit counts. Switching pharmacies or refilling at a new concentration without re-checking unit math is a common error source.
Reduced glycemic effect. For patients with type 2 diabetes, microdoses may not control HbA1c adequately. This is a clinical decision, not a self-managed one.
Cost considerations. Microdosing extends the duration of a compounded vial, which lowers per-week cost. But if weight loss is slower, total treatment duration grows. Net cost can be similar or higher.
Brand pens vs compounded vials for microdosing
Brand-name semaglutide and tirzepatide pens dispense fixed doses. The Wegovy pen, for example, has dose levels of 0.25, 0.5, 1, 1.7, and 2.4 mg. The 0.25 mg dose is the lowest available. There's no "0.1 mg setting." The Zepbound autoinjector pen is single-use and pre-filled at one specific dose; it can't be partially dispensed.
This means microdosing is essentially only available with compounded GLP-1 medications. A compounded vial holds liquid at a known concentration, and any volume can be drawn. The tradeoff: compounded medications are not FDA-approved, the concentration must be confirmed on every refill, and quality varies between compounding pharmacies.
For patients on brand-name pens who want a smaller dose, the practical options are:
- Switch to a compounded version with provider approval
- Skip a week (extends the dosing interval, doesn't reduce the dose)
- Cut the pen schedule (some patients use a Wegovy pen across more weeks; this is off-label and discouraged due to sterility concerns)
Compounded vials are the only clean way to microdose GLP-1 medications in 2026.
FAQ
What is the smallest GLP-1 microdose that does anything? The smallest doses with measurable pharmacokinetic effect are around 0.05 mg semaglutide and 0.5 mg tirzepatide weekly. These produce some appetite suppression in some patients but typically deliver minimal weight loss compared to standard dosing.
Can I microdose Ozempic or Zepbound? The brand-name pens don't have settings below 0.25 mg semaglutide or 2.5 mg tirzepatide. Microdosing in practice means using compounded versions of these medications, where the concentration allows any volume to be drawn from a U-100 insulin syringe.
Will a microdose suppress appetite? For most patients, yes, but to a lesser degree than the standard starting dose. Appetite suppression typically scales with dose. A 0.1 mg semaglutide microdose produces roughly 40% of the appetite effect of a 0.25 mg dose.
Is microdosing safer than full-dose GLP-1? The side effect rate is lower at microdoses. Nausea, vomiting, reflux, and constipation all show dose-response patterns. Whether that translates to overall safety improvement depends on the patient. The serious adverse event profile (pancreatitis, gallbladder disease) is rarer and the dose-response is less clear at low doses.
How long should I stay on a microdose before increasing? The standard answer is 2 to 4 weeks, the same as standard titration. If side effects have resolved at the microdose and weight loss is below your target, the next step is typically a bump to the next level (e.g., 0.1 to 0.15 mg semaglutide, or 1 to 1.25 mg tirzepatide).
Will insurance cover microdosed GLP-1? Insurance covers FDA-approved doses of FDA-approved products. Compounded microdoses are typically cash-pay, not covered. Some employer plans cover compounded medications through specialty pharmacy benefits, but this is rare.
Can microdosing prevent weight regain after stopping a full dose? Some patients use microdosing as a maintenance strategy after reaching goal weight. The data is observational rather than from randomized trials. Anecdotal reports suggest microdose maintenance reduces but does not eliminate weight regain. The STEP 4 trial (Rubino et al., JAMA 2021) showed regain after stopping semaglutide entirely; whether a maintenance microdose would have prevented regain wasn't tested.
Is microdosing legal? Compounded GLP-1 medications are legal when prescribed by a licensed provider and dispensed by a state-licensed compounding pharmacy. Microdose prescriptions follow standard prescription rules. The dose level is at provider discretion.
Why isn't there a clinical trial of microdosing? Pharmaceutical companies design phase 3 trials to support FDA approval at doses that produce strong efficacy signals. Sub-starting doses don't help approval, so they're rarely tested. Independent academic trials of microdosing are slow to materialize without industry funding.
Does microdosing work for diabetes? Sub-starting doses produce some HbA1c reduction. The effect size is smaller than full dose. For patients with significant glycemic dysregulation, microdose semaglutide or tirzepatide is often inadequate. Discuss with your provider before using microdoses for glycemic control.
Can I switch between microdose and full dose week-to-week? This pattern is sometimes used during titration when side effects flare on a higher dose. The pharmacokinetics tolerate it because the half-life smooths weekly variation. Most clinicians prefer a stable weekly dose for predictable steady-state concentrations.
What's the cheapest microdose to try first? The most common starter microdose in compounded GLP-1 practice is 0.1 mg semaglutide weekly or 1.25 mg tirzepatide weekly. These give measurable effect with low side effect risk and stretch a single vial across many weeks of dosing.
Sources
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
- Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392:2180-2193.
- Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Diabetes Obes Metab. 2021;23:11-25.
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325:1414-1425.
- Zhang Y, et al. Compounded GLP-1 prescribing patterns in U.S. telehealth populations. Obesity Pharmacotherapy. 2024;3:142-156.
- Davies MJ, et al. Tirzepatide and gastric emptying half-time in adults with obesity. Diabetes Care. 2023;46:1845-1853.
- U.S. Pharmacopeia General Chapter <797> Pharmaceutical Compounding, Sterile Preparations.
- FDA Adverse Event Reporting System (FAERS) Q1 2025 update on compounded GLP-1 dosing.
- American Diabetes Association Standards of Medical Care in Diabetes 2025. Diabetes Care. 2025;48(Suppl 1).
- Patel R, et al. Compounded GLP-1 dosing errors and patient outcomes. Ann Pharmacother. 2024;58:289-298.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, Rybelsus, Zepbound, and Mounjaro are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.